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Bone marrow mesenchymal stem cells (BMSCs) are adult multipotent stem cells that can diﬀerentiate into mesodermal lineage
cells, including adipocytes and osteoblasts. However, the epigenetic mechanisms governing the lineage-speciﬁc commitment of
BMSCs into adipocytes or osteoblasts are under investigation. Herein, we investigated the epigenetic eﬀect of romidepsin, a
small molecule dual inhibitor targeting HDAC1 and HDAC2 identiﬁed through an epigenetic library functional screen. BMSCs
exposed to romidepsin (5 nM) exhibited enhanced adipocytic and osteoblastic diﬀerentiation. Global gene expression and
signaling pathway analyses of diﬀerentially expressed genes revealed a strong enrichment of genes involved in adipogenesis and
osteogenesis in romidepsin-treated BMSCs during induction into adipocytes or osteoblasts, respectively. Pharmacological
inhibition of FAK signaling during adipogenesis or inhibition of FAK or TGFβ signaling during osteogenesis diminished the
biological eﬀects of romidepsin on BMSCs. The results of chromatin immunoprecipitation combined with quantitative
polymerase chain reaction indicated a signiﬁcant increase in H3K9Ac epigenetic markers in the promoter regions of peroxisome
proliferator-activated receptor gamma (PPARγ) and KLF15 (related to adipogenesis) or SP7 (Osterix) and alkaline phosphatase
(ALP) (related to osteogenesis) in romidepsin-treated BMSCs. Our data indicated that romidepsin is a novel in vitro modulator
of adipocytic and osteoblastic diﬀerentiation of BMSCs.
1. Introduction
Epigenetic modulation refers to heritable changes in
cellular gene expression via mechanisms that do not alter
underlying DNA sequences. One epigenetic mechanism is
the modulation of chromatin structure through histone
modiﬁcations, including acetylation, methylation, and phos-
phorylation. Histone acetylation is regulated by the balance
of opposing activities between histone acetyltransferases
(HATs) and histone deacetylases (HDACs), which are
important for the activation of gene transcription [1].
Chromatin architecture is an important factor in the regu-
lation of gene expression because, through the process of
active transcription, the compacted DNA is made accessi-
ble to RNA transcriptional machinery via epigenetic mod-
iﬁcation of the nucleosome. The changes in chromatin are
aﬀected via posttranslation modiﬁcations of histones; acet-
ylation of core histones is one of the most studied types of
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modiﬁcation implicated in regulating gene expression and
cellular diﬀerentiation [2].
Because of their ability to modify histones, histone
deacetylase inhibitors (HDACi) induce and regulate cell
diﬀerentiation and modulate tissue-speciﬁc gene expres-
sion. In embryonic stem cells, HDACi reduce self-
renewal by accelerating the expression of diﬀerentiation
markers [3]. Previous studies indicated that HDACi
enhanced the diﬀerentiation of human dental pulp stem
cells into osteoblasts [4] and the diﬀerentiation of 3T3-
L1 cells into adipocytes [5]. Valproic acid is an HDACi
reported to regulate the proliferation and self-renewal of
hematopoietic stem cells [6]. Glemzaite and Navakaus-
kiene [7] investigated the epigenetic changes occurring
during the diﬀerentiation of amniotic ﬂuid-derived hMSCs
into osteoblasts. The authors reported that HDAC1 and
HDAC2 were downregulated, which are associated with
an increase in H3K4me3 and H3K9Ac and which are
associated with an active chromatin state [7].
Bone marrow stromal stem cells (BMSCs) (also known
as skeletal or mesenchymal stem cells) are adult multipo-
tent stem cells with the capacity to diﬀerentiate into
mesodermal lineage cells, including adipocytes and osteo-
blasts [8]. To identify the molecular mechanisms underly-
ing their lineage fate, we performed an epigenetic-library
screen and identiﬁed a number of small molecule chemi-
cals that suggested possible molecular mechanisms. For
example, treatment of human BMSCs (hBMSCs) with the
HDACi, abexinostat, induced signiﬁcant changes in adipo-
cytic and osteoblastic diﬀerentiation [9], and CUDC-907, a
small molecule dual inhibitor of HDAC and PI3K,
enhanced adipocytic diﬀerentiation [10]. Herein, we inves-
tigated the biological eﬀects of romidepsin, a small mole-
cule dual inhibitor of HDAC1 and HDAC2 [11], on the
adipocytic and osteoblastic diﬀerentiation of hBMSCs and
identiﬁed its molecular mechanism.
2. Materials and Methods
We followed the methods of Ali et al. [9].
2.1. Compound. Romidepsin was purchased from Selleck-
chem (Selleckchem Inc., Houston, TX, USA). Prior to
use, romidepsin was dissolved in DMSO and used at a
concentration of 5 nM. Control cells were treated with
DMSO as the vehicle.
2.2. Cell Culture.We used a telomerized hBMSC line (hMSC-
TERT) as a model for BMSCs. The hMSC-TERT line was
created by overexpressing the human telomerase reverse
transcriptase gene (hTERT). hMSC-TERT expresses all
known markers of primary hBMSCs and exhibits “stemness”
characteristics owing to its ability to form a bone and bone
marrow microenvironment when implanted subcutaneously
in vivo [12]. These cells are hereafter referred to as hBMSCs.
Cells were cultured in a basal culture medium of Dulbecco’s
Modiﬁed Eagle’s medium (DMEM), supplemented with
4500mg/L D-glucose, 4mM L-glutamine, 110mg/L 10%
sodium pyruvate, 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and 1% nonessential amino acids.
All reagents were purchased from Thermo Fisher Scientiﬁc
Life Sciences (Waltham, MA, USA, http://www.thermoﬁsher
.com). Cells were incubated in 5% CO2 incubators at 37
°C
and 95% humidity. The cells were cultured to reach 80–90%
conﬂuence before addition of romidepsin. Romidepsin
was added at a concentration of 5 nM for 24h. Thereafter,
the cells were exposed to adipogenic or osteoblastic induc-
tion. Control cells were treated with basal medium con-
taining dimethyl sulfoxide (DMSO) as a vehicle. Normal
human primary hBMSCs were purchased from Thermo
Fisher Scientiﬁc Life Sciences.
2.3. Adipogenic Diﬀerentiation. The adipogenic induction
medium (AIM) consisted of DMEM supplemented with
10% FBS, 10% horse serum (Sigma-Aldrich, St. Louis, MO,
USA, https://www.sigmaaldrich.com), 1% penicillin/strepto-
mycin, 100 nM dexamethasone, 0.45mM isobutyl methyl
xanthine (Sigma-Aldrich), 3mg/mL insulin (Sigma-Aldrich),
and 1mM rosiglitazone (BRL49653). The AIM was replaced
every 3 days. Cells were assessed for adipogenic diﬀerentia-
tion on day 7.
2.4. Oil Red O and Nile Red Staining. Adipogenic diﬀerentia-
tion was determined by qualitative Oil Red O staining for
lipid-ﬁlled mature adipocytes. Cells were washed with
phosphate-buﬀered saline (PBS), ﬁxed with 4% paraformal-
dehyde for 10min, then incubated with freshly made and
ﬁltered (0.45mM) Oil Red O staining solution (0.05 g in
60% isopropanol; Sigma-Aldrich) for 1 h at room tempera-
ture. Nile red ﬂuorescence staining and quantiﬁcation of adi-
pogenesis were performed using a stock solution of Nile red
(1mg/mL) in DMSO that was stored at −20°C and protected
from light. Staining was performed on unﬁxed cells. Cultured
diﬀerentiated cells were grown in polystyrene ﬂat-bottom 96-
well tissue culture- (TC-) treated black microplates (Corning
Inc., Corning, NY, USA, http://www.corning.com) and
washed once with PBS. The dye was then added directly to
the cells at a ﬁnal concentration of 5μg/mL in PBS, and the
preparation was incubated for 10min at room temperature,
then washed twice with PBS. The ﬂuorescent signal was
measured using a SpectraMax/M5 ﬂuorescence spectropho-
tometer plate reader (Molecular Devices Co., Sunnyvale,
CA, USA, https://www.moleculardevices.com) using the
bottom well-scan mode, during which nine readings were
taken per well using excitation (485 nm) and emission
(572 nm) spectra. Oil Red and Nile red ﬂuorescence were
imaged using an EVOS Cell Imaging System (Thermo Fisher
Scientiﬁc Life Sciences).
2.5. Osteogenic Diﬀerentiation. hBMSCs were cultured as
noted in the previous section and exposed to osteogenic
induction medium (DMEM containing 10% FBS, 1% penicil-
lin-streptomycin, 50mg/mL L-ascorbic acid (Wako Chemi-
cals GmbH, Neuss, Germany, https://www.wakochemicals
.de/), 10mM β-glycerophosphate (Sigma-Aldrich), 10 nM
calcitriol (1a, 25-dihydroxy vitamin D3; Sigma-Aldrich),
and 100nM dexamethasone (Sigma-Aldrich)).
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2.6. Alkaline Phosphatase (ALP) Staining and Activity
Quantiﬁcation.We used a BioVision ALP activity colorimet-
ric assay kit (BioVision, Inc., Milpitas, CA, USA, https://www
.biovision.com/) with some modiﬁcations. Cells were cul-
tured in 96-well plates under normal or osteogenic induction
conditions. On day 10, wells were rinsed once with PBS and
ﬁxed using 3.7% formaldehyde in 90% ethanol for 30 s at
room temperature. The ﬁxative was removed, and 50μL of
p-nitrophenyl phosphate solution was added to each well.
The plates were incubated for 20–30min in the dark at room
temperature until a clear yellow color developed. The
reaction was subsequently stopped by adding 20μL of stop
solution. Optical density was then measured at 405 nm using
a SpectraMax/M5 ﬂuorescence spectrophotometer plate
reader. For ALP staining, the cells were washed in PBS,
ﬁxed in acetone/citrate buﬀer, and incubated with ALP
substrate solution (naphthol AS-TR phosphate 0.1M Tris
buﬀer, pH9.0) for 1 h at room temperature. Images were
taken using an EVOS Cell Imaging System (Thermo
Fisher Scientiﬁc Life Sciences).
2.7. RNA Extraction and cDNA Synthesis. The total RNA was
isolated from cell pellets after 7 days of adipogenic diﬀerenti-
ation and 10 days of osteogenic diﬀerentiation using a Total
RNA Puriﬁcation Kit (Norgen Biotek Corp., Thorold, ON,
Canada, https://norgenbiotek.com/) according to the manu-
facturer’s protocol. The total RNA concentration was
measured using a NanoDrop 2000 (Thermo Fisher Scientiﬁc
Life Sciences). cDNA was synthesized using 500ng of total
RNA and the Thermo Fisher Scientiﬁc Life Sciences High
Capacity cDNA Transcription Kit according to the manu-
facturer’s protocol.
2.8. Quantitative Real-Time PCR. The expression levels of
adipogenic-related genes and validation of selected upregu-
lated genes in the microarray data (AP2, AdipoQ, PPARγ2,
CEBPα, PCK1, CNTFR, LPL, LIPE, and ACACB) were quan-
tiﬁed using Fast SYBR Green Master Mix and a ViiA 7 Real-
Time PCR device (Thermo Fisher Scientiﬁc Life Sciences).
The primers used for gene expression analysis and validation
are listed in Table 1. For osteoblast-related gene expression,
custom TaqMan low-density array cards were used (Thermo
Fisher Scientiﬁc Life Sciences). The assay ID for the primer
sets used for the osteoblast gene panel is provided in
supplementary Table 1. The 2DCT value method was used
to calculate relative expression, and data was analyzed as
previously described [13].
2.9. DNA Microarray Gene Expression Proﬁling. The total
RNA (150ng) was labeled using the low input Quick Amp
Labeling Kit (Agilent Technologies, Santa Clara, CA, USA),
then hybridized to the Agilent SurePrint G3 Human GE
8× 60 kmicroarray chip (Agilent Technologies). All microar-
ray experiments were performed at the Microarray Core
Facility (Stem Cell Unit, King Saud University College of
Medicine, Riyadh, Saudi Arabia). The extracted data were
normalized and analyzed using GeneSpring 13.0 software
(Agilent Technologies). Pathway analysis was performed
using the Single Experiment Pathway analysis feature in
GeneSpring 13.0 (Agilent Technologies) as previously
described [14]. Twofold cutoﬀ and a P < 0 05 were used to
enrich for signiﬁcantly changed transcripts.
2.10. Western Blotting. Total cellular protein was extracted
using RIPA lysis solution (Norgen Biotek Corp., Thorold,
ON, Canada). The protein (10μg) was resolved using Mini-
PROTRAN®TGX™ Stain Free precast gels and transferred
to a PVDF membrane using a Trans-Blot® Turbo™ Mini
PVDF Transfer Pack (Bio-Rad Laboratories, Hercules, CA,
USA). Blots were incubated with primary antibodies over-
night at 4°C in TBS-Tween (0.05%) with 5% nonfat milk at
the designated dilution for H3 (Lys9) (C5B11) rabbit mono-
clonal antibody (mAb) (1 : 1000; catalog number 9649, Cell
Signaling Technology, Danvers, MA, USA, https://www
.cellsignal.com) and di-methyl-histone H3 (Lys4) (C64G9)
rabbit mAb (1 : 1000; catalog number 9725, Cell Signaling
Technology). The membrane was subsequently incubated
with anti-rabbit IgG HRP conjugated antibody (1 : 3000
dilution, Cell Signaling Technology, #7074p2). Membranes
were probed using HRP-conjugated anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody (1 : 10,000,
ab9482; Abcam, Cambridge, MA, USA, http://www.abcam
.com) as a loading control. Imaging was conducted using
the ChemiDoc MP imager (Bio-Rad Laboratories). Band
intensity was quantiﬁed using the band quantiﬁcation tool
in the Image Laboratory 5.0 software (Bio-Rad Laboratories).
Data were presented as the fold increase of normalized (to
Table 1: List of SYBR green primers used in current study.
No. Name Sequence
1 AdipoQ
F 5′ GCAGTCTGTGGTTCTGATTCCATAC
R 5′ GCCCTTGAGTCGTGGTTTCC
2 AP2
F 5′ TGGTTGATTTTCCATCCCAT
R 5′ GCCAGGAATTTGACGAAGTC
3 CEBPA
F 5′ TATAGGCTGGGCTTCCCCTT
R 5′ AGCTTTCTGGTGTGACTCGG
4 PPARγ2
F 5′ TTCTCCTATTGACCCAGAAAGC
R 5′ CTCCACTTTGATTGCACTTTGG
5 PCK1
F 5′ TTACCAATGTGGCCGAGACC
R 5′ GCACAAGGTTCCCCATCCTC
6 CNTFR
F 5′ GCGACTCTAGCCTTGTCACC
R 5′ GACTGTGTCTCTGGGCGTAG
7 LPL
F 5′ CTTGGAGATGTGGACCAGC
R 5′ GTGCCATACAGAGAAATCTC
8 LIPE
F 5′ AGCCACGATGGGTGGAATG
R 5′ ACCAGCGACTGTGTCATTGT
9 ACACB
F 5′ ACAGTCCTGAGATCCCCCTC
R 5′ GTTCAGCCGGGTGGACTTTA
10 β-actin
F 5′ AGCCATGTACGTTGCTA
R 5′ AGTCCGCCTAGAAGCA
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GAPDH) signal intensity of romidepsin-treated cells com-
pared with DMSO-treated cells.
2.11. Chromatin Immunoprecipitation and qPCR Validation.
hMSC-TERT cells (vehicle (DMSO) treated or romidepsin
24 h treated) were ﬁxed with 1% formaldehyde for 15min
and quenched with 0.125M glycine. Chromatin was isolated
by adding lysis buﬀer and disrupting with a Dounce homog-
enizer. Lysates were sonicated, and the DNA was sheared to
an average length of 300–500 base pairs. Genomic DNA
(input) was prepared by treating aliquots of chromatin with
RNase, proteinase K, and heat for decrosslinking, followed
by ethanol precipitation. Pellets were resuspended, and the
resulting DNA was quantiﬁed using a NanoDrop spectro-
photometer. Extrapolation to the original chromatin volume
allowed quantiﬁcation of the total chromatin yield. An ali-
quot of chromatin (30μg) was precleared using protein A
agarose beads (Invitrogen). Genomic DNA regions of inter-
est were isolated using antibodies against H3K9Ac. Com-
plexes were washed, eluted from the beads with SDS buﬀer,
and subjected to RNase and proteinase K treatment. Cross-
links were reversed by overnight incubation at 65°C, and
ChIP DNA was puriﬁed by phenol-chloroform extraction
and ethanol precipitation. For quality assurance, quantitative
PCR (qPCR) reactions were carried out in triplicate on
speciﬁc genomic regions using SYBR Green Supermix (Bio-
Rad Laboratories). The resulting signals were normalized
for primer eﬃciency by performing qPCR for each primer
pair using input DNA. All ChIP-seq experiments were
performed by the Active Motif Epigenetic Service (Active
Motif, Carlsbad, CA, USA).
2.12. HDAC Enzymatic Activity Assay. HDAC enzymatic
activity in control or treated hMSC-TERT cells was measured
using the HDAC-Glo I/II assay and screening system (Pro-
mega Inc., Madison, WI, USA, https://www.promega.com/)
according to the manufacturer’s protocol. Brieﬂy, 1× 104
cells in a volume of 50μL were seeded per well in a white-
walled 96-well plate and incubated with the inhibitor mixture
at 37°C for 30min. Trichostatin A was used as a positive
control (supplied with the kit). HDAC-Glo I/II reagent (con-
taining the substrate and the developer reagent) was added,
and the solution was incubated at room temperature for
45min. Luminescence was measured using a SpectraMax/
M5 ﬂuorescence spectrophotometer plate reader.
2.13. Inhibition of FAK and Transforming Growth Factor β
(TGFβ) Signaling during Adipogenic and Osteogenic
Diﬀerentiation. hBMSCs were cultured in 96-well plates.
After exposure to romidepsin or vehicle control for 24h,
normal culture medium was replaced with adipogenic and
osteogenic induction medium supplemented with FAK
inhibitor (PF-573228) at 5μM (Sigma-Aldrich) or trans-
forming growth factor β (TGFβ) signaling inhibitor
(SB505124) at 1μM (Sigma-Aldrich). Adipogenic and osteo-
genic media were supplemented with inhibitors and replaced
every 2 days. On day 7, Nile red was quantiﬁed to assess adi-
pogenic diﬀerentiation, and on day 10, ALP was quantiﬁed to
determine osteogenic diﬀerentiation, as indicated above.
3. Results
3.1. Romidepsin Promoted Adipocytic Diﬀerentiation of
hBMSCs. Romidepsin is an HDACi that primarily targets
HDAC1 and HDAC2. The compound was initially identiﬁed
through a functional screen of an epigenetic library consist-
ing of 24 compounds based on its ability to promote adipocy-
tic and osteocytic diﬀerentiation of hBMSCs, as previously
described [9].
To investigate the mechanism by which romidepsin pro-
motes bone marrow adipogenesis, hBMSCs were incubated
with romidepsin (5 nM) for 24h, followed by induction of
adipocyte diﬀerentiation. hBMSC s exposed to romidepsin
exhibited enhanced adipocyte diﬀerentiation, as indicated
by higher Oil Red O staining (Figure 1(a)). Qualitative and
quantitative analyses of mature adipocytes using Nile red
staining (Figure 1(b)) and quantiﬁcation (Figure 1(c))
revealed a signiﬁcant increase (~1.5-fold, P < 0 0005;
Figure 1(c)) in adipogenesis. Nile red quantiﬁcation indi-
cated that romidepsin promoted adipocyte diﬀerentiation
in primary normal hBMSCs in a similar manner (~2.5-fold
increase, P < 0 0005; Figure 1(d)).
3.2. Romidepsin Enhanced Adipocytic Gene Networks. To
understand the molecular process by which romidepsin
promoted adipocytic diﬀerentiation, global gene expression
proﬁling of hBMSCs exposed to romidepsin and induced
into adipocytes for 7 days was determined. Hierarchical clus-
tering based on diﬀerentially expressed transcripts showed
clear separation of the romidepsin-treated and control cells
(Figure 2(a)). We identiﬁed 794 upregulated and 852
downregulated transcripts (>2.0 FC, P (Corr)< 0.05;
Supplementary Table 2). Pathway analysis of the diﬀeren-
tially expressed genes revealed signiﬁcant enrichment of
genes associated with several cellular processes, including
focal adhesion and adipogenesis. The pie chart in Figure 2(d)
depicts the top 15 enriched pathways. A selected gene panel
from the genes identiﬁed by microarray analysis data based
on their involvement in adipogenesis-related processes,
including AdipoQ, AP2, PPARγ2, CEBPα, CNTFR, LPL,
LIPE, ACACB, and PCK1, was chosen for validation
using qRT-PCR (Figure 2(c)). Concordant with the
microarray data, inhibition of the FAK pathway using
PF-573228 signiﬁcantly inhibited the stimulatory eﬀects
of romidepsin (P < 0 0005; Figure 2(d)).
3.3. Eﬀect of Romidepsin on Osteoblastic Diﬀerentiation of
hBMSCs. We assessed the eﬀect of romidepsin on the osteo-
blastic diﬀerentiation of hBMSCs. Cells were exposed to
romidepsin for 24 h before exposing hBMSCs to osteoblastic
induction media. On postinduction day 10, more ALP stain-
ing was observed in romidepsin-treated cells compared with
vehicle-treated control cells (Figures 3(a)–3(c)). Similarly,
ALP quantiﬁcation revealed signiﬁcantly higher ALP activity
in the romidepsin-treated cells compared to that in the
control cells (~2.0-fold increase, P < 0 05; Figure 3(d)). The
stimulatory eﬀect on osteoblasts was further validated using
primary hBMSCs, which exhibited a signiﬁcant increase in
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ALP activity in romidepsin-treated cells compared to that in
control cells (~1.5-fold increase, P < 0 005).
3.4. Romidepsin Enhanced Osteoblastic Gene Networks.
Global gene expression proﬁling was conducted on hBMSCs
following exposure to romidepsin and osteoblastic induc-
tion for 10 days compared to that on vehicle-treated
control cells. Hierarchical clustering based on diﬀerentially
expressed transcripts showed clear separation between the
romidepsin-treated and control cells (Figure 4(a)). We
identiﬁed 3989 upregulated and 4315 downregulated tran-
scripts (>2.0 FC, P (corr)< 0.05; Supplementary Table 3).
Pathway analysis of the upregulated genes revealed strong
enrichment for several cellular processes involved in oste-
oblastic diﬀerentiation, including focal adhesion, WNT
signaling, and TGFβ pathway (Figure 4(b)). We selected
a group of genes from those that exhibited signiﬁcant
changes in the microarray analysis, based on their association
with osteogenesis-related processes: ALP, OC, ON, RUNX2,
IGF1R, CSF1, BGLAP, SP7, TGFBR2, TGFB2, ALPL,
DLX5, SPP1, and NOG, using qRT-PCR (Figure 4(c)). Con-
cordant with the microarray data, inhibition of FAK
(using PF-573228) or TGFβ (using SB505124) diminished
the osteogenesis-promoting eﬀects of romidepsin (P <
0 005, Figure 4(d)).
3.5. Romidepsin Promoted Adipogenesis and Osteogenesis via
Inhibition of HDAC. To identify the molecular mechanism
by which romidepsin promoted adipocytic and osteocytic
diﬀerentiation, hBMSCs treated with romidepsin for 24h
were examined for diﬀerent histone markers using Western
blotting. The results indicated increased levels of H3K9Ac
and H3K4me2, which are associated with actively transcribed
genomic regions (Figure 5(a)). The increase in those
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Figure 1: Eﬀects of romidepsin treatment on the diﬀerentiation of human bone marrow stromal stem cells (hMSCs) into adipocytes. hMSCs
were induced to diﬀerentiate into adipocytes in the presence of romidepsin (5 nM) or vehicle control for 24 h. The eﬀects on adipocyte
diﬀerentiation were examined at day 7. (a) Representative Oil Red O staining of lipid-ﬁlled mature adipocytes; (b) Nile red staining
images were captured at ×20 and ×40 magniﬁcation using an EVOS Cell Imaging System; (c) the level of Nile red staining was quantiﬁed,
and data are representative of three independent experiments; (d) Nile red staining quantiﬁcation in primary hBMSCs. Data are presented
as mean± SEM, n = 15, ∗∗∗P < 0 0005 from three independent experiments.
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Figure 2: Microarray gene expression proﬁling of adipocyte-diﬀerentiated human bone marrow stromal stem cells (hMSCs) following
romidepsin treatment. (a) Heat map and unsupervised hierarchical clustering were performed on diﬀerentially expressed genes in
romidepsin-treated hMSCs compared to those in vehicle-treated control hMSCs on day 7 after adipocyte diﬀerentiation. (b) Pie chart
illustrating the distribution of the top 15 enriched pathway categories in the diﬀerentially expressed genes identiﬁed in romidepsin-treated
hMSCs. (c) Validation of a selected group of upregulated genes identiﬁed by microarray analysis using qRT-PCR. Gene expression was
normalized to β-actin. Data are presented as mean fold changes± SEM compared with vehicle-treated controls; n = 6 from two
independent experiments, ∗P < 0 05 and ∗∗∗P < 0 0005 comparing romidepsin-treated and control cells. (d) Quantiﬁcation of Nile red
staining for mature adipocytes in romidepsin-treated hMSCs and in the absence or presence of a FAK inhibitor (5 μM). Data are
presented as mean± SEM, n = 6, ∗∗P < 0 005, and ∗∗∗P < 0 0005.
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epigenetic markers was associated with a signiﬁcant decrease
in HDAC activity (~70% reduction, P < 0 0005; Figure 5(b)).
Trichostatin A- (TA-) treated cells were used as positive
control (Figure 5(b)).
3.6. ChIP-qPCR Data Revealed Signiﬁcant Enrichment in
Multiple Genes Related to Adipogenesis and Osteogenesis.
We subsequently sought to determine the promoter regions
in hBMSCs targeted by romidepsin using CHIP assay with
H3K9Ac antibody. The immune-precipitated genomic
DNA was subjected to qPCR for the promoter regions of
PPARG, KLF15 (related to adipogenesis) and SP7, ALPL
(related to osteogenesis). The results indicated a signiﬁcant
increase in the H3K9Ac epigenetic marker in the promoter
regions of these genes in response to romidepsin treatment,
likely through the inhibition of HDAC1 and HDAC2
(Figure 5(c)).
4. Discussion
Understanding the molecular mechanism underlying the dif-
ferentiation fate choice of hMSCs into osteoblasts and adipo-
cytes is important for understanding disease processes in
which hMSC diﬀerentiation is aﬀected, for example, bone
fragility in age-related osteoporosis and obesity [15]. In the
current study, we report the use of a chemical biology
approach using a known HDACi to uncover the relevance
of epigenetic regulation in hBMSC diﬀerentiation. We iden-
tiﬁed a number of genes and genetic pathways that are rele-
vant for both osteoblast and adipocyte diﬀerentiation.
In our studies, we employed a cell model, hMSC-
TERT, for hBMSCs which has been created through over-
expression of human telomerase reverse transcriptase gene
(hTERT). The hMSC-TERT cells express known markers
of primary hBMSCs, exhibit stemness characteristics, and
are able to form bone and bone marrow microenviron-
ment when implanted in vivo [12, 16]. Our previous gene
expression proﬁling highlighted the similarities of the
molecular phenotype of hMSC-TERT cells and primary
hBMCs [17]. Previous data showed that HDAC inhibition
reduces telomerase protein expression and activity which
may confound the results obtained in our study. However,
we obtained similar eﬀects of romidepsin on osteoblastic
and adipocytic diﬀerentiation in primary bone marrow
MSCs (Figures 1(d) and 3(e)) obtained from normal
healthy donor suggesting that the observed eﬀects of
D
M
SO
Ro
m
id
ep
sin
(a)
DMSO
(b)
Romidepsin
(c)
250
200
150
%
 A
LP
 ac
tiv
ity
100
50
0
DMSO Romidepsin
⁎
(d)
200
150
100
%
 A
LP
 ac
tiv
ity
50
0
DMSO Romidepsin
⁎⁎
(e)
Figure 3: Eﬀect of romidepsin treatment on the diﬀerentiation of human bone marrow stromal stem cells (hMSCs) into osteoblasts. hMSCs
were induced to osteoblastic diﬀerentiation in the presence of romidepsin (5 nM) or vehicle control for 24 h. The eﬀects on osteoblastic
diﬀerentiation were examined at day 10. (a) ALP staining for romidepsin-treated compared to vehicle-treated control cells (4x
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activity; (e) validation of quantiﬁcation of ALP activity in romidepsin-treated versus vehicle-treated control cells in primary hMSCs. Data
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Figure 4: Microarray gene expression proﬁling of osteoblast-diﬀerentiated human bone marrow stromal stem cells (hMSCs) following
romidepsin treatment. (a) Heat map and unsupervised hierarchical clustering were performed on diﬀerentially expressed genes induced by
romidepsin compared to those of vehicle-treated control hMSCs at day 10 after osteoblastic diﬀerentiation; (b) Pie chart illustrating the
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(c) validation of the selected gene panel during osteoblastic diﬀerentiation using qRT-PCR. Gene expression was normalized to β-
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romidepsin on hBMSC diﬀerentiation are not related to its
eﬀects on telomerase activity.
In the current study, we investigated romidepsin, an
HDAC1 and HDAC2 inhibitor, that has been used as an
anticancer drug and is known to induce cancer cell cycle
arrest, cancer cell diﬀerentiation, and cell death [18]. We
observed that hMSCs are more sensitive to romidepsin
because the biological eﬀects were observed at a much
lower dose (5 nM) compared to the biologically eﬀective
dose of two small molecule epigenetic modiﬁers, abexino-
stat and CUDC-907, that we reported previously [9]
[10]. We observed that romidepsin induced adipocytic dif-
ferentiation through the upregulation of adipocyte-
associated transcriptional factors known to be required
for adipocyte diﬀerentiation, for example, peroxisome
proliferator-activated receptor gamma 2 (PPARγ2) and
CCAAT/enhancer binding protein α (CEBPα) [19–21]
and other genes relevant to adipogenesis, including ADI-
POQ, AP2, PCK1, LPL, and LIPE. These genes are impor-
tant for both adipocyte lineage commitment and
maturation [22]. Among the upregulated genes, ACACB
is part of the adipocytokine signaling pathway and CNTFR
is known to prevent neuronal degeneration. Additionally,
the expression of these genes has been implicated in adi-
pogenesis leading to obesity and diabetes [23, 24]. We
observed that approximately 48% of the upregulated genes
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HDAC enzymatic activity of romidepsin-treated hMSCs (30min) compared with control cells. Trichostatin A was used as a positive
control. Data are presented as mean± SEM from two independent experiments, n = 11, ∗∗∗P < 0 0005. (c) H3K9Ac ChIP-qPCR for the
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diﬀerentiation of hMSCs by romidepsin through ampliﬁcation of the FAK and TGFβ signaling pathways. ∗P < 0 05; ∗∗P < 0 005.
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in romidepsin-treated hMSCs that were induced to diﬀeren-
tiate into adipocytes were also upregulated in either abexino-
stat- or CUDC-907-treated hMSCs, suggesting a common
mechanism of action for these compounds.
Romidepsin treatment enhanced the diﬀerentiation of
hBMSCs into osteoblasts through upregulation of a number
of osteogenic gene markers, including ALP, OC, ON, and
RUNX2 [25]. Insulin-like growth factor 1 receptor (IGF1R)
signaling, which regulates Osterix (SP7), and RUNX2 are
important factors in bone formation during development
and in the postnatal organism [26–28]. In addition, another
upregulated gene in romidepsin-treated cells was DLX5,
which activates bone formation directly through activation
of RUNX2 [29].
We reported that romidepsin treatment uncovered
important genetic pathways that are common or speciﬁc to
the diﬀerentiation of hBMSCs into osteoblasts and adipo-
cytes. Romidepsin treatment enhanced the FAK intracellular
signaling pathway known to regulate BMSC diﬀerentiation to
osteogenic or adipogenic lineage [30, 31]. For example, Hu
et al. reported that changes in cellular physical environment
by shockwave treatment enhanced osteogenesis via activa-
tion of FAK signaling followed by activation of ERK1/2 and
RUNX2 [32]. On the other hand, disruption of FAK signaling
in the preadipocyte cell line, 3T3L1 cells, or in vivo in mice
decreased adipocyte cell diﬀerentiation and impaired insulin
sensitivity [33].
In addition to its eﬀect on FAK signaling, romidepsin
enhanced two osteoblast-associated signaling pathways:
TGFβ andWnt signaling. TGFβ is important for the prolifer-
ation, commitment, and diﬀerentiation of BMSCs to osteo-
blastic lineages directly and through cross-talk with other
intracellular signaling pathways such as BMPs and Wnt
[34]. The importance of TGFβ isoforms and their receptors
in skeletal biology and BMSC diﬀerentiation and functions
has been demonstrated by the presence of signiﬁcant skeletal
defects in TGFβ genetically modiﬁed animals; for example,
TGFβ2 knockout mice showed lack of distal parts of the ribs
[35], transgenic mice with negative form of TGFβ2 devel-
oped hypoplastic cartilage, multiple defects in the base of
the skull and vertebrae, defects in long bones and joints
[36], and important for cartilage maintenance and preven-
tion of osteoarthritis in human and mice models [37].
Wnt signaling functions are a potent regulator of oste-
ogenesis in hBMSC, and its inhibition is accompanied by
inhibition of osteoblastic diﬀerentiation [38]. Gaur et al.
reported that canonical Wnt signaling is signiﬁcantly
linked to RUNX2 which is a target for β-catenin/TCF1
nuclear translocation, a signaling pathway required for
osteoblastic diﬀerentiation and bone formation [39]. We
have previously demonstrated that hBMSCs carrying acti-
vation mutation of Lrp5 (Wnt coreceptor) lead to
enhanced Wnt signaling and osteoblast diﬀerentiation but
inhibit adipocyte diﬀerentiation [40].
Our data suggest that romidepsin magniﬁed the eﬀects
of osteoblast and adipocyte induction media. We observed
that following treatment with romidepsin, H3K9Ac histone
marks were increased suggesting an active state of chro-
matin and increased the accessibility of transcription
factors to their target genes, inducing osteogenic and adi-
pocytic diﬀerentiation [41]. This model is supported by
the ChIP-qPCR results and gene expression analysis that
demonstrated a signiﬁcant upregulation of Kruppel-like
factors (KLFs). KLFs are a member of a family of C2H2
zinc ﬁnger proteins known to regulate adipocyte diﬀerenti-
ation [42]. KLF15 has been reported to synergistically
interact with CEBPα to induce adipogenesis via increasing
the activity of PPARγ2 and CEBPα. In addition, PPARγ2
induces the adipogenic diﬀerentiation program with induc-
tion of adipogenic genes, such as AP2 and Adipo Q.
While these eﬀects are known to take place in extramedul-
lary adipogenic diﬀerentiation [43], our data suggest simi-
lar eﬀects on bone marrow adipocytes. For osteoblastic cell
diﬀerentiation and mineralized matrix formation, the coor-
dinated eﬀects of bone-speciﬁc transcriptional factors, SP7
(Osterix) and RUNX2, are needed [44]. Our ChIP-qPCR
corroborated these concepts as it revealed a signiﬁcant
increase in the H3K9Ac marks at the SP7 promoter
region. Figure 5(d) presents our current working hypothe-
sis regarding the interaction of romidepsin and HDAC
inhibition in hBMSC lineage fate determination.
5. Conclusions
The study of the epigenetic pathways that modulate the
adipogenic and osteogenic diﬀerentiation of hBMSCs pro-
vides useful information and insight into the understand-
ing of the cross-talk between the epigenetic eﬀect of
HDACi, transcription factors, and diﬀerentiation path-
ways. The ability to manipulate intracellular signaling
pathways associated with hBMSC diﬀerentiation state can
optimize the use of hBMSCs in clinical applications and
regenerative medicine.
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